To include your compound in the COVID-19 Resource Center, submit it here.

Cor reports 6-month ESPRIT data

CORR and partner Schering-Plough (SGP) reported follow-up data from their Phase IV ESPRIT study showing a 7.5

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE